JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma.

Lingkai Meng,Tao Huang,Wang Li,Yue Yu,Ling Ding

doi:10.1155/2020/7973568

Abstract

Background Stomach adenocarcinoma (STAD) is one of the most common malignant tumors. The Janus kinases (JAKs) play a significant part in cellular biological process, inflammation, and immunity. The roles of JAKs in STAD are still not systematically described. Methods A series of bioinformatics tools were used to clarify the role of JAKs in STAD. Results JAK3/TYK2 levels were significantly increased in STAD during subgroup analyses based on gender, tumor grade, cancer stages, and nodal metastasis status. STAD patients with high levels of JAK3/TYK2 had poor overall survival, postprogression survival, and first progression. Immune infiltration revealed a significant correlation between JAK3/TYK2 expression and the abundance of immune cells as well as immune biomarker expression in STAD. JAK3/TYK2 was associated with the adaptive immune response, chemokine signaling pathway, and JAK-STAT signaling pathway. Conclusions JAK3 and TYK2 serve as prognostic biomarkers and are associated with immune infiltration in STAD.

Highlights

Gastric cancer (GC) is one of the most common malignant tumors, with the fifth largest incidence and third largest mortality rate among all malignant tumors [1]
We analyzed the correlation between the expression levels of JAK3/TYK2 and the clinicopathological parameters of Stomach adenocarcinoma (STAD) patients
The mRNA levels of JAK3 were significantly increased in STAD during subgroup analyses based on the race, gender, age, H. pylori infection status, histological subtype, tumor grade, cancer stage, and nodal metastasis status of patients (Figure 2)

Summary

Introduction

Gastric cancer (GC) is one of the most common malignant tumors, with the fifth largest incidence and third largest mortality rate among all malignant tumors [1]. The molecular mechanisms concerning the tumorigenesis and progress of GC is far from clarified and the therapeutic measures for GC are limited, resulting in a poor patient prognosis. The overall survival of patients with advanced or metastatic GC is only approximately 1 year [3]. These sobering data illustrate a critical need for novel prognostic biomarkers and therapeutic targets for STAD. JAK3/TYK2 levels were significantly increased in STAD during subgroup analyses based on gender, tumor grade, cancer stages, and nodal metastasis status. STAD patients with high levels of JAK3/TYK2 had poor overall survival, postprogression survival, and first progression. JAK3 and TYK2 serve as prognostic biomarkers and are associated with immune infiltration in STAD

Objectives

Methods

Results

Conclusion